Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2021-12-30 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司公司章程(2021年12月）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for 江苏四环生物股份有限公司, covering company organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. It references Chinese company law and securities law, and extensively details the rules and procedures for shareholder meetings, board and management roles, share issuance and repurchase, and other corporate governance topics. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a meeting presentation or transcript, nor a voting result announcement. The document is a governance document outlining internal rules and structure of the company. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail confirm it is the actual governance document, not just an announcement or summary.
2021-12-30 Chinese
四环生物2021年第二次临时股东大会法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the procedures, attendance, voting, and resolutions of the 2021 second extraordinary general meeting (临时股东大会) of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It reviews the convening, voting methods, attendance qualifications, and voting results of the shareholders' meeting. The document does not contain financial statements or financial performance data but focuses on the legal compliance of the shareholders' meeting process and resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, but it is not a direct announcement of voting results nor a proxy solicitation. It fits best under Legal Proceedings Report (LTR) as it provides a legal opinion on the meeting's legality and compliance with laws and regulations.
2021-12-30 Chinese
江苏四环生物股份有限公司2021年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2021 second extraordinary general meeting of shareholders of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the meeting date, voting procedures, attendance, and the voting results on various proposals such as amendments to the company charter and appointment of non-independent directors. It also includes a legal opinion on the validity of the meeting and resolutions. The document is not a full report but an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2182 characters, which is relatively short and consistent with an announcement rather than a full report.
2021-12-30 Chinese
江苏四环生物股份有限公司独立董事工作制度
Governance Information Classification · 95% confidence The document is titled 'Independent Director Work System' and details the governance structure, roles, responsibilities, nomination, election, rights, and obligations of independent directors in the company. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and outlines internal governance rules rather than financial data or report results. There is no indication of financial statements, audit results, earnings data, or shareholder meeting materials. The content is focused on governance practices and internal rules related to board members, specifically independent directors. Therefore, this document fits best under Governance Information (CGR). The document length is 4394 characters, which is sufficient for a detailed governance policy but not a full financial report or announcement.
2021-12-30 Chinese
独立董事关于变更会计师事务所的事前认可书
Board/Management Information Classification · 95% confidence The document is a formal statement from independent directors regarding the pre-approval of changing the company's accounting firm. It references compliance with stock exchange listing rules and internal governance procedures. The content focuses on governance and approval processes related to auditor changes, not on financial results, audit reports, or annual reports themselves. The document is short (442 characters) and does not contain financial data or audit opinions. It is an announcement related to board/management decisions about auditor changes, fitting the category of Board/Management Information (MANG).
2021-12-27 Chinese
关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders for Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the meeting date, voting methods, attendees, agenda items (including changing the 2021 audit firm), and voting instructions. It does not contain any financial statements or results but is an announcement of a shareholder meeting and related procedural information. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is 2840 characters, which is consistent with a meeting notice rather than a full report or results announcement.
2021-12-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.